Tiova Rotacap is a brand name for the inhalation medication tiotropium bromide which belongs to the class of anticholinergic drugs used for the management of chronic obstructive pulmonary disease. It functions by binding selectively to muscarinic receptors in the airway smooth muscle preventing acetylcholine from inducing bronchoconstriction. This competitive antagonism results in sustained relaxation of the bronchial passages and improved airflow. The drug is administered via a dry powder inhaler that delivers the medication directly to the lungs where it is absorbed locally to achieve a high concentration at the site of action. Because tiotropium has a long elimination half-life its effect persists for up to 24 hours after a single dose. The primary therapeutic purpose is to reduce symptom burden such as dyspnea and exacerbations in patients with copd. Pharmacodynamically the blockade of cholinergic signaling leads to decreased intracellular calcium influx which relaxes airway smooth muscle fibers. Over time repeated use maintains bronchodilation and facilitates better disease control.

Tiova Rotacap is a brand name for an inhalation medication containing tiotropium bromide. It belongs to the class of long-acting anticholinergic bronchodilators used in the management of chronic obstructive pulmonary disease. The drug works by blocking muscarinic receptors in the airway smooth muscle, leading to relaxation of bronchial passages. This receptor antagonism reduces bronchoconstriction and improves airflow during respiration. Pharmacologically, tiotropium has a high affinity for the m3 subtype of cholinergic receptors, which are primarily responsible for airway tone regulation. Its long duration of action results from a slow dissociation from the receptor, providing sustained bronchodilation for up to 24 hours after a single dose. The therapeutic purpose of Tiova Rotacap is to decrease the frequency of exacerbations and improve lung function in patients with copd. By maintaining open airways, the medication helps relieve symptoms such as wheezing, shortness of breath, and chronic cough.

Tiova Rotacap may cause dry mouth. Tiova Rotacap can cause throat irritation. Tiova Rotacap sometimes results in headache. Tiova Rotacap can cause sinus congestion. Tiova Rotacap may produce dizziness. Tiova Rotacap can cause eye irritation. Tiova Rotacap may result in constipation. Tiova Rotacap sometimes leads to urinary retention.

Dry mouth is frequently reported as a mild side effect of Tiova Rotacap inhalation. Some users experience irritation of the throat or oral cavity after dosing. Coughing can occur, especially during the first few days of treatment. Headaches are occasionally observed in patients using this medication. Dizziness may be noted, particularly in individuals sensitive to anticholinergic agents. Nausea has been listed as a less common but possible gastrointestinal reaction. Skin rash or itching can develop as an allergic response in some patients. Mild urinary symptoms such as increased frequency have been documented in clinical studies.